<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31366366</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Jul</Month><Day>31</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the virucidal effects of rosmarinic acid against enterovirus 71 infection via in vitro and in vivo study.</ArticleTitle><Pagination><StartPage>94</StartPage><MedlinePgn>94</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">94</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-019-1203-z</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although enterovirus 71 (EV71) is an important public health threat, especially in the Asia-Pacific region, there are still no effective drugs or vaccines to treat and prevent EV71 infection. Therefore, it is critical to develop prophylactic and therapeutic agents against EV71. Rosmarinic acid (RA), a phytochemical, has been discovered to possess a broad spectrum of biological activities.</AbstractText><AbstractText Label="METHODS">The virucidal effects of RA on EV71 were determined by MTT, western blot, median cell culture infectious dose, apoptosis detection, plaque reduction, semi-quantitative real-time polymerase chain reaction, immunofluorescence detection, molecular docking analysis, and mouse protection assay.</AbstractText><AbstractText Label="RESULTS">RA showed a strong protective effect against EV71 infection in human rhabdomyosarcoma cells when the multiplicity of infection was 1, with a low IC<sub>50</sub> value (4.33&#x2009;&#xb1;&#x2009;0.18&#x2009;&#x3bc;M) and high therapeutic index (340). RA not only protected cells from EV71-induced cytopathic effects, but also from EV71-induced apoptosis. The results of time-of-addition analysis demonstrated that the inhibitory activity of RA was highest at the early stage of viral infection. Consistent with this, the infectivity of EV71 in the early stage of viral infection also was observed to be limited in neonatal mice treated with RA. Further, molecular docking predicts that RA could replace the natural pocket factor within the VP1 capsid-binding hydrophobic pocket.</AbstractText><AbstractText Label="CONCLUSIONS">This study suggests that RA has the potential to be developed as an antiviral agent against initial EV71 infection to prevent or reduce EV71-induced pathogenesis and complications, since RA can effectively reduce EV71 infection in the early stages of viral infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wen-Yu</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>School of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yu-Jen</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>School of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jinn</LastName><ForeName>Tzyy-Rong</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0001-7176-4807</Identifier><AffiliationInfo><Affiliation>School of Chinese Medicine, China Medical University, Taichung, 40402, Taiwan, Republic of China. jinn@mail.cmu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002934">Cinnamates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053630">Depsides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002934" MajorTopicYN="N">Cinnamates</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003588" MajorTopicYN="N">Cytopathogenic Effect, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053630" MajorTopicYN="N">Depsides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097123" MajorTopicYN="N">Rosmarinic Acid</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">Herbal medicine</Keyword><Keyword MajorTopicYN="N">Molecular docking</Keyword><Keyword MajorTopicYN="N">Neonatal mice</Keyword><Keyword MajorTopicYN="N">Rosmarinic acid</Keyword><Keyword MajorTopicYN="N">Virucidal efficacy</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31366366</ArticleId><ArticleId IdType="pmc">PMC6670152</ArticleId><ArticleId IdType="doi">10.1186/s12985-019-1203-z</ArticleId><ArticleId IdType="pii">10.1186/s12985-019-1203-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chang PC, Chen SC, Chen KT. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13:890&#x2013;904. doi: 10.3390/ijerph13090890.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph13090890</ArticleId><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments towards control of human enterovirus 71. Crit Rev Microbiol. 2011;37:313&#x2013;327. doi: 10.3109/1040841X.2011.580723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang J, Wang L, Ma S, Liu Y. Anti-enterovirus 71 agents of natural products. Molecules. 2015;20:16320&#x2013;16333. doi: 10.3390/molecules200916320.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules200916320</ArticleId><ArticleId IdType="pmc">PMC6331931</ArticleId><ArticleId IdType="pubmed">26370955</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Tao L, Xu U. Chinese herbal medicines as a source of molecules with anti-enterovirus 71 activity. Chin Med. 2016;11:2&#x2013;27. doi: 10.1186/s13020-016-0074-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13020-016-0074-0</ArticleId><ArticleId IdType="pmc">PMC4731985</ArticleId><ArticleId IdType="pubmed">26834824</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89:2518&#x2013;2530. doi: 10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Xiu J, Zhang L, Qin C, Liu J. Antiviral activity of punicalagin toward human enterovirus 71 in vitro and in vivo. Phytomedicine. 2012;20:67&#x2013;70. doi: 10.1016/j.phymed.2012.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2012.08.012</ArticleId><ArticleId IdType="pubmed">23146421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Xiu J, Liu J, Zhang L, Li X, Xu Y, et al. Chebulagic acid, a hydrolyzable tannin, exhibited antiviral activity in vitro and in vivo against human enterovirus 71. Int J Mol Sci. 2013;14:9618&#x2013;9627. doi: 10.3390/ijms14059618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms14059618</ArticleId><ArticleId IdType="pmc">PMC3676802</ArticleId><ArticleId IdType="pubmed">23644889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Hsieh FC, Lin YJ, Wu TY, Lin CW, Lin CT, et al. Magnesium lithospermate B and rosmarinic acid, two compounds presents in Salvia miltiorrhiza, have potent antiviral activity against enterovirus 71 infections. Eur J Pharmacol. 2015;755:127&#x2013;133. doi: 10.1016/j.ejphar.2015.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2015.02.046</ArticleId><ArticleId IdType="pubmed">25773498</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M, Simmonds MS. Rosmarinic acid. Phytochemistry. 2003;62:121&#x2013;125. doi: 10.1016/S0031-9422(02)00513-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-9422(02)00513-7</ArticleId><ArticleId IdType="pubmed">12482446</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoah SKS, Sandjo LP, Kratz JM, Biavatti MW. Rosmarinic acid-pharmaceutical and clinical aspects. Planta Med. 2016;82:388&#x2013;406. doi: 10.1055/s-0035-1568274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0035-1568274</ArticleId><ArticleId IdType="pubmed">26845712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim GD, Park YS, Jim YH, Park CS. Production and applications of rosmarinic acid and structurally related compounds. Appl Microbiol Bioyechnol. 2015;99:2083&#x2013;2092. doi: 10.1007/s00253-015-6395-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-015-6395-6</ArticleId><ArticleId IdType="pubmed">25620368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulgakov VP, Inyushkina YV, Fedoreyov SA. Rosmarinic acid and its derivatives: biotechnology and applications. Crit Rev Biotechnol. 2012;32:203&#x2013;217. doi: 10.3109/07388551.2011.596804.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07388551.2011.596804</ArticleId><ArticleId IdType="pubmed">21838541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto Y, Ikeda S, Uwai K, Taguchi R, Chayama K, Sakaguchi T, et al. Rosmarinic acid is a novel inhibitor for hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS One. 2018;13:0197664. doi: 10.1371/journal.pone.0197664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197664</ArticleId><ArticleId IdType="pmc">PMC5962091</ArticleId><ArticleId IdType="pubmed">29782545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan YK, Sam IC, AbBakar S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol. 2010;10:404&#x2013;412. doi: 10.1016/j.meegid.2009.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2009.05.010</ArticleId><ArticleId IdType="pubmed">19465162</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang DJ, Zhang C, Zhang RG, Wu WD, Chen SY, Ren JC, et al. Involvement of inducible nitric oxide synthase and mitochondrial dysfunction in the pathogenesis of enterovirus 71 infection. Oncotarget. 2017;46:81014&#x2013;81026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655258</ArticleId><ArticleId IdType="pubmed">29113363</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KYA, Chen MF, Huang YC, Shih SR, Chiu CH, Lin JJ, Wang JR, et al. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun. 2017;8:762. doi: 10.1038/s41467-017-00736-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00736-9</ArticleId><ArticleId IdType="pmc">PMC5624920</ArticleId><ArticleId IdType="pubmed">28970483</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Gao Z, Zhong YY, Bao LL, Xu L, Deng W, et al. Histopathological features and distribution of EV71 antigens and SCAB2 in human fatal cases and a mouse model of enterovirus 71 infection. Virus Res. 2014;189:121&#x2013;132. doi: 10.1016/j.virusres.2014.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.05.006</ArticleId><ArticleId IdType="pubmed">24842162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroneman A, Vennema H, Deforche K, Avoort H, Pe&#xf1;aranda S, et al. An automated genotyping tool for enteroviruses and noroviruses. J Clin Virol. 2011;5:121&#x2013;125. doi: 10.1016/j.jcv.2011.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2011.03.006</ArticleId><ArticleId IdType="pubmed">21514213</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J, Wang YX, Sun YN, Huang JY, Yan WZ, Wang JL, et al. Cyclophilin a associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 2014;10:1&#x2013;15. doi: 10.1371/journal.ppat.1004422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004422</ArticleId><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Cifuene JO, Ashley RE, Conway JF, Makhov AM, Tano Y, et al. A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J Virol. 2013;87:11363&#x2013;11370. doi: 10.1128/JVI.01926-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01926-13</ArticleId><ArticleId IdType="pmc">PMC3807339</ArticleId><ArticleId IdType="pubmed">23946455</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Xiaohua, Fan Chen, Ku Zhiqiang, Zuo Teng, Kong Liangliang, Zhang Chao, Shi Jinping, Liu Qingwei, Chen Tan, Zhang Yingyi, Jiang Wen, Zhang Linqi, Huang Zhong, Cong Yao. Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. PLOS Pathogens. 2016;12(3):e1005454. doi: 10.1371/journal.ppat.1005454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005454</ArticleId><ArticleId IdType="pmc">PMC4777393</ArticleId><ArticleId IdType="pubmed">26938634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995;8:127&#x2013;134. doi: 10.1093/protein/8.2.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/8.2.127</ArticleId><ArticleId IdType="pubmed">7630882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci. 2014;21:31. doi: 10.1186/1423-0127-21-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-21-31</ArticleId><ArticleId IdType="pmc">PMC4013435</ArticleId><ArticleId IdType="pubmed">24742252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Qiao H, Lv Y, Wang J, Chen X, Hou Y, et al. Apigenin inhibits enterovirus 71 infection by disrupting viral RNA association with trans-acting factors. PLoS One. 2014;9:110429. doi: 10.1371/journal.pone.0110429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0110429</ArticleId><ArticleId IdType="pmc">PMC4199717</ArticleId><ArticleId IdType="pubmed">25330384</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Li Y, Gu Z, Wang Y, Shi M, Ji Y, et al. Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-kappaB signaling pathway. PLoS One. 2015;10:e0116879. doi: 10.1371/journal.pone.0116879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0116879</ArticleId><ArticleId IdType="pmc">PMC4333343</ArticleId><ArticleId IdType="pubmed">25692777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Tao L, Fu WW, Liang S, Yang YF, Yuan QH, et al. Prenylated benzoylphloroglucinols and xanthones from the leaves of garcinia oblongifolia with antienteroviral activity. J Nat Prod. 2014;77:1037&#x2013;1046. doi: 10.1021/np500124e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/np500124e</ArticleId><ArticleId IdType="pubmed">24679044</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi HJ, Song JH, Park KS, Baek SH. In vitro anti-enterovirus 71 activity of gallic acid from Woodfordia fruticosa flowers. Lett Appl Microbiol. 2010;50:438&#x2013;440. doi: 10.1111/j.1472-765X.2010.02805.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1472-765X.2010.02805.x</ArticleId><ArticleId IdType="pubmed">20149083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bemard A, Lacroxic C, Cabiddu MG, Neyts J, Leyssen P, Pompei R. Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds. Antivir Chem Chemother. 2015;24:56&#x2013;61. doi: 10.1177/2040206615589035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206615589035</ArticleId><ArticleId IdType="pmc">PMC5890516</ArticleId><ArticleId IdType="pubmed">26071135</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L, Wang X, Spyrou JAB, Kelly J, Ren J, Grimes J, et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21:282&#x2013;288. doi: 10.1038/nsmb.2769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2769</ArticleId><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Yu J, Hao F, He H, Shi X, Hu J, et al. Discovery of potent EV71 capsid inhibitors for treatment of HFMD. ACS Med Chem Lett. 2017;8:841&#x2013;846. doi: 10.1021/acsmedchemlett.7b00188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.7b00188</ArticleId><ArticleId IdType="pmc">PMC5554915</ArticleId><ArticleId IdType="pubmed">28835799</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110:5463&#x2013;5467. doi: 10.1073/pnas.1222379110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222379110</ArticleId><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>